Early research (Phase 1)Active Not RecruitingNCT05259839
What this trial is testing
Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 283